WASHINGTON (AP) — The wealth of Dr. Mehmet Oz, the celebrity heart surgeon nominated by President Donald Trump to lead the Centers for Medicare and Medicaid Services, has swelled in part from ...

Researchers from Analysis Group , a global leader in health economics and outcomes research (HEOR), have co-developed a new framework that leverages findings from clinical trials and real-world ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Although a waiver was placed on HIV/AIDS programmes in last month's U.S. foreign aid funding freeze, many concerns remained about the future of treatment programmes, the deputy executive director of ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...